Pathological classification of prostate cancer

Written by Zhou Zi Hua
Oncology
Updated on September 19, 2024
00:00
00:00

The classification of precancerous lesions of prostate cancer is divided into two categories: intraductal carcinoma of the prostate and atypical adenomatous hyperplasia. Among these, the relationship between intraductal carcinoma of the prostate and prostate cancer is the closest. Intraductal carcinoma of the prostate is currently recognized as a precancerous lesion of prostate cancer, while atypical adenomatous hyperplasia has not been proven to be a precancerous lesion of prostate cancer according to current evidence. However, the biological behavior of this atypical adenomatous hyperplasia is not very clear yet, so it should be closely monitored. The histological classification of prostate cancer mainly includes the majority of acinar adenocarcinoma and a small amount of ductal adenocarcinoma, with acinar adenocarcinoma being a highly invasive malignant tumor.

Other Voices

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
51sec home-news-image

Endocrine therapy after radical prostatectomy for prostate cancer

Endocrine therapy after radical prostatectomy for prostate cancer is equivalent to adjuvant endocrine therapy for prostate cancer. Its purpose is to treat residual lesions, positive residual lymph nodes, and microscopic metastatic foci, thereby improving long-term survival rates. Currently, the indications for adjuvant endocrine therapy are based on postoperative pathology-positive results, positive lymph nodes post-surgery, and postoperative pathology confirmation of stage T3 or T4, but with high-risk factors. According to major guidelines, the duration of adjuvant endocrine therapy should be at least eighteen months.

doctor image
home-news-image
Written by Liu Liang
Oncology
36sec home-news-image

Is prostate cancer sexually transmitted?

Prostate cancer is non-contagious; therefore, it cannot be transmitted through sharing utensils, eating together, or through respiratory pathways. Secondly, prostate cancer is not transmitted through sexual activity; it is non-contagious. In clinical settings, many family members of patients inquire whether malignant tumors are contagious and if they could be infected while caring for the patient. It is important to clarify that malignant tumors are not contagious, and prostate cancer cannot be transmitted through sexual activity.

doctor image
home-news-image
Written by Liu Liang
Oncology
40sec home-news-image

Can prostate cancer patients eat eggs?

Patients with prostate conditions can eat eggs, as eggs are a high-protein food. Since cancer is a consumptive disease, it is important for patients to maintain a balanced diet, including meat, protein, vegetables, and fruits to ensure nutritional balance. Some cancer patients, particularly those in advanced stages who have poor appetite, may develop hypoalbuminemia due to inadequate nutrition. Such patients can benefit from consuming more eggs or protein supplements like protein powder to increase their protein intake. Patients with prostate cancer can eat eggs.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
34sec home-news-image

How long can one live after prostate cancer has spread to the bones?

Bone metastasis is the most common site of metastasis for prostate cancer. If a patient with prostate cancer develops bone metastasis, it means that the cancer is no longer in its early stages and has progressed to a more advanced stage. However, unlike other cancers with a higher degree of malignancy, if the tumor is highly sensitive to hormone therapy, with standardized treatment, the patient's survival time can be significantly extended.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
40sec home-news-image

Prostate Cancer Treatment Options

How is prostate cancer treated? The choice of treatment plan should be based on a comprehensive consideration of the patient's clinical stage, age, overall health, and expected lifespan. For example, in the early stages of prostate cancer, one can choose postoperative radical radiotherapy after prostatectomy. For locally advanced prostate cancer, radiotherapy, intensified radiotherapy combined with endocrine therapy can be chosen. For metastatic prostate cancer, endocrine therapy is mainly used, and chemotherapy can be adopted for those who are ineffective or fail endocrine therapy.